Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.

Morishima T, Krahl AC, Nasri M, Xu Y, Aghaallaei N, Findik B, Klimiankou M, Ritter M, Hartmann MD, Gloeckner CJ, Stefańczyk S, Lindner C, Oswald B, Bernhard R, Hähnel K, Hermanutz-Klein U, Ebinger M, Handgretinger R, Casadei N, Welte K, Andre M, Müller P, Bajoghli B, Skokowa J.

Blood. 2019 Jul 31. pii: blood.2019000095. doi: 10.1182/blood.2019000095. [Epub ahead of print]

PMID:
31366618
2.

CRISPR/Cas9 mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients.

Nasri M, Ritter M, Mir P, Dannenmann B, Aghaallaei N, Amend D, Makaryan V, Xu Y, Fletcher B, Bernhard R, Steiert I, Hahnel K, Berger J, Koch I, Sailer B, Hipp K, Zeidler C, Klimiankou M, Bajoghli B, Dale DC, Welte K, Skokowa J.

Haematologica. 2019 Jun 27. pii: haematol.2019.221804. doi: 10.3324/haematol.2019.221804. [Epub ahead of print]

3.

Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia.

Klimiankou M, Uenalan M, Kandabarau S, Nustede R, Steiert I, Mellor-Heineke S, Zeidler C, Skokowa J, Welte K.

Front Immunol. 2019 Feb 28;10:116. doi: 10.3389/fimmu.2019.00116. eCollection 2019.

4.

Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.

Nasri M, Mir P, Dannenmann B, Amend D, Skroblyn T, Xu Y, Schulze-Osthoff K, Klimiankou M, Welte K, Skokowa J.

Blood Adv. 2019 Jan 8;3(1):63-71. doi: 10.1182/bloodadvances.2017015511.

5.

Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34+ cells preceding leukemic transformation.

Dannenmann B, Zahabi A, Mir P, Oswald B, Bernhard R, Klimiankou M, Morishima T, Schulze-Osthoff K, Zeidler C, Kanz L, Lachmann N, Moritz T, Welte K, Skokowa J.

Exp Hematol. 2019 Mar;71:51-60. doi: 10.1016/j.exphem.2018.12.006. Epub 2019 Jan 4.

PMID:
30615903
6.

Role of CSF3R mutations in the pathomechanism of congenital neutropenia and secondary acute myeloid leukemia.

Klimiankou M, Mellor-Heineke S, Zeidler C, Welte K, Skokowa J.

Ann N Y Acad Sci. 2016 Apr;1370(1):119-25. doi: 10.1111/nyas.13097.

PMID:
27270496
7.

Two cases of cyclic neutropenia with acquired CSF3R mutations, with 1 developing AML.

Klimiankou M, Mellor-Heineke S, Klimenkova O, Reinel E, Uenalan M, Kandabarau S, Skokowa J, Welte K, Zeidler C.

Blood. 2016 May 26;127(21):2638-41. doi: 10.1182/blood-2015-12-685784. Epub 2016 Mar 30. No abstract available.

8.

ELANE mutant-specific activation of different UPR pathways in congenital neutropenia.

Nustede R, Klimiankou M, Klimenkova O, Kuznetsova I, Zeidler C, Welte K, Skokowa J.

Br J Haematol. 2016 Jan;172(2):219-27. doi: 10.1111/bjh.13823. Epub 2015 Nov 16.

PMID:
26567890
9.

GM-CSF stimulates granulopoiesis in a congenital neutropenia patient with loss-of-function biallelic heterozygous CSF3R mutations.

Klimiankou M, Klimenkova O, Uenalan M, Zeidler A, Mellor-Heineke S, Kandabarau S, Skokowa J, Zeidler C, Welte K.

Blood. 2015 Oct 8;126(15):1865-7. doi: 10.1182/blood-2015-07-661264. Epub 2015 Aug 31. No abstract available.

10.

Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.

Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, Unalan M, Kandabarau S, Makaryan V, Beekman R, Behrens K, Stocking C, Obenauer J, Schnittger S, Kohlmann A, Valkhof MG, Hoogenboezem R, Göhring G, Reinhardt D, Schlegelberger B, Stanulla M, Vandenberghe P, Donadieu J, Zwaan CM, Touw IP, van den Heuvel-Eibrink MM, Dale DC, Welte K.

Blood. 2014 Apr 3;123(14):2229-37. doi: 10.1182/blood-2013-11-538025. Epub 2014 Feb 12.

11.

Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.

Gupta K, Kuznetsova I, Klimenkova O, Klimiankou M, Meyer J, Moore MA, Zeidler C, Welte K, Skokowa J.

Blood. 2014 Apr 17;123(16):2550-61. doi: 10.1182/blood-2012-09-456889. Epub 2014 Jan 6.

12.

A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation.

Klimenkova O, Ellerbeck W, Klimiankou M, Ünalan M, Kandabarau S, Gigina A, Hussein K, Zeidler C, Welte K, Skokowa J.

Blood. 2014 Feb 20;123(8):1239-49. doi: 10.1182/blood-2013-06-508887. Epub 2013 Dec 18.

13.

Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis.

Skokowa J, Klimiankou M, Klimenkova O, Lan D, Gupta K, Hussein K, Carrizosa E, Kusnetsova I, Li Z, Sustmann C, Ganser A, Zeidler C, Kreipe HH, Burkhardt J, Grosschedl R, Welte K.

Nat Med. 2012 Oct;18(10):1550-9. doi: 10.1038/nm.2958. Epub 2012 Sep 23.

14.

The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells.

Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K, Skokowa J.

Haematologica. 2012 Apr;97(4):551-9. doi: 10.3324/haematol.2011.055236. Epub 2011 Dec 29.

15.

Supplemental Content

Loading ...
Support Center